Pharvaris N.V. (NASDAQ:PHVS) Stock Now Rated “Moderate Buy” by Wall Street Brokerages

Pharvaris N.V. (NASDAQ:PHVS) has earned a consensus recommendation of “Moderate Buy” from the fifteen ratings firms that are presently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation and thirteen have issued a buy recommendation on the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $59.87.

PHVS has been the subject of a number of recent research reports. Citigroup reissued a “market outperform” rating on shares of Pharvaris in a research note on Wednesday, September 9th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Pharvaris in a report on Friday, July 17th. Morgan Stanley boosted their price target on Pharvaris from $46.00 to $62.00 and gave the stock an “overweight” rating in a research report on Wednesday, September 9th. Cantor Fitzgerald restated an “overweight” rating and set a $65.00 price objective on shares of Pharvaris in a research note on Monday, September 14th. Finally, Citizens Jmp raised their price objective on Pharvaris from $75.00 to $79.00 and gave the company a “market outperform” rating in a research report on Wednesday, September 9th.

Insider Buying and Selling at Pharvaris

In related news, Director Elisabeth Bjork sold 52,500 shares of the stock in a transaction that occurred on Thursday, September 17th. The shares were sold at an average price of $37.89, for a total transaction of $1,989,225.00. Following the completion of the sale, the director owned 15,167 shares of the company’s stock, valued at $574,677.63. This represents a 77.59% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO David W. Nassif sold 6,000 shares of the stock in a transaction that occurred on Monday, September 21st. The shares were sold at an average price of $36.47, for a total transaction of $218,820.00. Following the sale, the chief financial officer directly owned 114,300 shares of the company’s stock, valued at $4,168,521. The trade was a 4.99% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 513,102 shares of company stock valued at $18,643,666.

Hedge Funds Weigh In On Pharvaris

A number of large investors have recently made changes to their positions in the business. venBio Partners LLC acquired a new stake in shares of Pharvaris in the 2nd quarter worth $160,569,809. Wellington Management Group LLP raised its stake in Pharvaris by 12.9% in the second quarter. Wellington Management Group LLP now owns 2,392,934 shares of the company’s stock valued at $82,748,000 after buying an additional 274,034 shares during the last quarter. Commodore Capital LP boosted its holdings in Pharvaris by 1.6% in the first quarter. Commodore Capital LP now owns 1,918,970 shares of the company’s stock worth $54,211,000 after acquiring an additional 29,525 shares in the last quarter. 5AM Venture Management LLC acquired a new stake in Pharvaris in the second quarter worth about $27,581,008. Finally, Seven Fleet Capital Management LP grew its stake in shares of Pharvaris by 144.6% during the second quarter. Seven Fleet Capital Management LP now owns 774,501 shares of the company’s stock worth $26,782,000 after acquiring an additional 457,804 shares during the last quarter.

Pharvaris Stock Performance

NASDAQ PHVS opened at $30.49 on Tuesday. The company has a market capitalization of $1.99 billion, a price-to-earnings ratio of -10.00 and a beta of -2.46. The company’s 50-day simple moving average is $34.98 and its two-hundred day simple moving average is $32.22. Pharvaris has a one year low of $20.65 and a one year high of $43.25.

Pharvaris (NASDAQ:PHVS) last announced its quarterly earnings results on Wednesday, August 12th. The company reported ($0.81) earnings per share for the quarter, missing the consensus estimate of ($0.75) by ($0.06). Equities analysts expect that Pharvaris will post -3.12 earnings per share for the current fiscal year.

Pharvaris Company Profile

Pharvaris N.V. (NASDAQ:PHVS) is a biopharmaceutical company focused on developing oral therapies for hereditary angioedema (HAE) and other diseases associated with bradykinin-mediated swelling. HAE is a rare genetic disorder that can cause recurring, potentially life-threatening attacks affecting areas such as the skin, gastrointestinal tract and airways.

The company’s lead program is deucrictibant, an orally administered small-molecule bradykinin B2 receptor antagonist formerly known as PHA121.